CXCR4 Polyclonal Antibody

This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

The CXCR4 Polyclonal Antibody is a highly specific and reliable tool designed for the detection and analysis of CXCR4 protein expression in various biological samples. This antibody is produced using advanced immunization techniques, ensuring high affinity and sensitivity.

The CXCR4 Polyclonal Antibody exhibits exceptional performance in a wide range of applications, including Western blotting, immunohistochemistry, and flow cytometry. It has been extensively validated for its specificity and minimal cross-reactivity with other related proteins, guaranteeing accurate and reproducible results.

With its superior quality and performance, the CXCR4 Polyclonal Antibody is an indispensable tool for researchers and scientists working in the fields of immunology, oncology, and cell biology. Its versatility and reliability make it an ideal choice for studying CXCR4-mediated signaling pathways and investigating the role of CXCR4 in various physiological and pathological processes.

The CXCR4 Polyclonal Antibody is supplied in a convenient and ready-to-use format, ensuring ease of use and saving valuable time in the laboratory. It is available in different sizes to accommodate various experimental needs. Each batch of the antibody undergoes rigorous quality control procedures to ensure consistent and reliable performance.

Choose the CXCR4 Polyclonal Antibody for its exceptional specificity, sensitivity, and versatility, and unlock new insights into the complex mechanisms involving CXCR4 protein expression.